April 7th, 2014
Selections from Richard Lehman’s Literature Review: April 7th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include SYMPLICITY HTN-3, CoreValve, MADIT-CRT, and more.
March 30th, 2014
Long-Term Follow-Up from MADIT-CRT: Guideline Implications
Arthur J. Moss, MD
Arthur J. Moss discusses his research group’s study of long-term survival for patients who received cardiac resynchronization therapy with a defibrillator in the MADIT-CRT trial.
September 17th, 2010
FDA Grants Expanded Indication to CRT-D Devices
Larry Husten, PHD
The FDA has expanded the indication for CRT-D devices made by Boston Scientific. Previously, the devices had been approved only in NYHA Class III and IV patients. The expanded indication now includes Class I and II patients who have left bundle branch block. The expanded indication is based on data from the MADIT-CRT trial. “This approval […]
NEJM Journal Watch — Recent Cardiology Articles- More Data on Finerenone for Heart Failure with Preserved or Mildly Reduced Ejection Fraction
- Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long Is Long Enough?